TTRX
Turn Therapeutics Inc.
Biotechnology
Market Cap$112M
5Y Perf.-11.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TTRX vs ARQT
Revenue, margins, valuation, and 5-year total return — side by side.
ARQT
Arcutis Biotherapeutics, Inc.
Biotechnology
Market Cap$2.58B
5Y Perf.-9.6%
TTRX vs ARQT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TTRX | ARQT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $112M | $2.58B |
| Revenue (TTM) | — | $416M |
| Net Income (TTM) | $-2M | $-2M |
| Gross Margin | — | 90.9% |
| Operating Margin | — | 0.8% |
| Forward P/E | — | 106.5x |
| Total Debt | $121K | $6M |
| Cash & Equiv. | $873K | $43M |
Quick Verdict: TTRX vs ARQT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TTRX and ARQT are tied at the top with 2 categories each — the right choice depends on your priorities. Arcutis Biotherapeutics, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
TTRX
Turn Therapeutics Inc.
The Income Pick
TTRX has the current edge in this matchup, primarily because of its strength in income & stability and sleep-well-at-night.
- beta 1.45
- Lower volatility, beta 1.45, current ratio 1.55x
- Beta 1.45, current ratio 1.55x
Best for: income & stability and sleep-well-at-night
ARQT
Arcutis Biotherapeutics, Inc.
The Long-Run Compounder
ARQT is the clearest fit if your priority is long-term compounding.
- -5.2% 10Y total return vs TTRX's -45.8%
- +50.8% vs TTRX's -45.8%
- -0.6% ROA vs TTRX's -87.1%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Quality / Margins | TTRX | 1.4% margin vs ARQT's -0.6% |
| Stability / Safety | TTRX | Beta 1.45 vs ARQT's 1.48 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ARQT | +50.8% vs TTRX's -45.8% |
| Efficiency (ROA) | ARQT | -0.6% ROA vs TTRX's -87.1% |
TTRX vs ARQT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2023
TTRX vs ARQT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLARQTLAGGINGTTRX
TTRXTurn Therapeutics Inc.
0leads
ARQTArcutis Biotherapeuti…
2leads
6 Total Categories
CATEGORYLEADERvs TTRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
—
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ARQT4/5
Total Returns1Y, 3Y, 5Y total returns with dividends
ARQT5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
| Metric | TTRXTurn Therapeutics… | ARQTArcutis Biotherap… |
|---|---|---|
| RevenueTrailing 12 months | — | $416M |
| EBITDAEarnings before interest/tax | — | $6M |
| Net IncomeAfter-tax profit | — | -$2M |
| Free Cash FlowCash after capex | — | $27M |
| Gross MarginGross profit ÷ Revenue | — | +90.9% |
| Operating MarginEBIT ÷ Revenue | — | +0.8% |
| Net MarginNet income ÷ Revenue | — | -0.6% |
| FCF MarginFCF ÷ Revenue | — | +6.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +60.1% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +55.0% |
Insufficient data to determine a leader in this category.
Valuation Metrics
Insufficient data to determine a leader in this category.
Valuation Metrics
| Metric | TTRXTurn Therapeutics… | ARQTArcutis Biotherap… |
|---|---|---|
| Market CapShares × price | $112M | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $111M | $2.5B |
| Trailing P/EPrice ÷ TTM EPS | — | -158.92x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 106.49x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 6.87x |
| Price / BookPrice ÷ Book value/share | — | 13.87x |
| Price / FCFMarket cap ÷ FCF | — | — |
Insufficient data to determine a leader in this category.
Profitability & Efficiency
ARQT leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), ARQT scores 4/9 vs TTRX's 3/9, reflecting mixed financial health.
| Metric | TTRXTurn Therapeutics… | ARQTArcutis Biotherap… |
|---|---|---|
| ROE (TTM)Return on equity | — | -1.4% |
| ROA (TTM)Return on assets | -87.1% | -0.6% |
| ROICReturn on invested capital | — | -5.2% |
| ROCEReturn on capital employed | -125.5% | -4.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | -$751,563 | -$37M |
| Cash & Equiv.Liquid assets | $872,599 | $43M |
| Total DebtShort + long-term debt | $121,036 | $6M |
| Interest CoverageEBIT ÷ Interest expense | — | 2.08x |
ARQT leads this category, winning 4 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
ARQT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ARQT five years ago would be worth $6,053 today (with dividends reinvested), compared to $5,421 for TTRX. Over the past 12 months, ARQT leads with a +50.8% total return vs TTRX's -45.8%. The 3-year compound annual growth rate (CAGR) favors ARQT at 13.2% vs TTRX's -18.5% — a key indicator of consistent wealth creation.
| Metric | TTRXTurn Therapeutics… | ARQTArcutis Biotherap… |
|---|---|---|
| YTD ReturnYear-to-date | -19.1% | -28.8% |
| 1-Year ReturnPast 12 months | -45.8% | +50.8% |
| 3-Year ReturnCumulative with dividends | -45.8% | +44.9% |
| 5-Year ReturnCumulative with dividends | -45.8% | -39.5% |
| 10-Year ReturnCumulative with dividends | -45.8% | -5.2% |
| CAGR (3Y)Annualised 3-year return | -18.5% | +13.2% |
ARQT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TTRX and ARQT each lead in 1 of 2 comparable metrics.
Risk & Volatility
TTRX is the less volatile stock with a 1.45 beta — it tends to amplify market swings less than ARQT's 1.48 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ARQT currently trades 65.0% from its 52-week high vs TTRX's 14.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TTRXTurn Therapeutics… | ARQTArcutis Biotherap… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.45x | 1.50x |
| 52-Week HighHighest price in past year | $26.50 | $31.77 |
| 52-Week LowLowest price in past year | $2.57 | $12.42 |
| % of 52W HighCurrent price vs 52-week peak | +14.3% | +65.0% |
| RSI (14)Momentum oscillator 0–100 | 61.1 | 54.3 |
| Avg Volume (50D)Average daily shares traded | 23K | 1.3M |
Evenly matched — TTRX and ARQT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TTRX as "Buy" and ARQT as "Buy".
| Metric | TTRXTurn Therapeutics… | ARQTArcutis Biotherap… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $35.50 |
| # AnalystsCovering analysts | 1 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ARQT leads in 2 of 6 categories — strongest in Profitability & Efficiency and Total Returns. 1 category is tied.
Best OverallArcutis Biotherapeutics, In… (ARQT)Leads 2 of 6 categories
Loading custom metrics...
TTRX vs ARQT: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is TTRX or ARQT a better buy right now?
Analysts rate Turn Therapeutics Inc.
(TTRX) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TTRX or ARQT?
Over the past 5 years, Arcutis Biotherapeutics, Inc.
(ARQT) delivered a total return of -39. 5%, compared to -45. 8% for Turn Therapeutics Inc. (TTRX). Over 10 years, the gap is even starker: ARQT returned -2. 9% versus TTRX's -45. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TTRX or ARQT?
By beta (market sensitivity over 5 years), Turn Therapeutics Inc.
(TTRX) is the lower-risk stock at 1. 45β versus Arcutis Biotherapeutics, Inc. 's 1. 50β — meaning ARQT is approximately 3% more volatile than TTRX relative to the S&P 500.
04Which has better profit margins — TTRX or ARQT?
Turn Therapeutics Inc.
(TTRX) is the more profitable company, earning 0. 0% net margin versus -4. 3% for Arcutis Biotherapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TTRX leads at 0. 0% versus -3. 3% for ARQT. At the gross margin level — before operating expenses — ARQT leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — TTRX or ARQT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is TTRX or ARQT better for a retirement portfolio?
For long-horizon retirement investors, Turn Therapeutics Inc.
(TTRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (TTRX: -45. 9%, ARQT: -2. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between TTRX and ARQT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TTRX is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.